MedTrace Logo

BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

NCT05813132 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-09-05

No results posted yet for this study

Summary

The proposed research aims to compare between BeEAM standard regimen and CEM as conditioning regimen in lymphoma patients in safety profile\& toxicity, infections (Febrile neutropenia) during transplant, time to engraftment (recovery not neutropenic), Length of stay at hospital, time to relapse, and other complications.

Conditions

Interventions

DRUG

BEAM Protocol

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)

DRUG

CEM protocol

CEM (Carboplatin, Etoposide, Melphalan)

Sponsors & Collaborators

  • Rehab Werida

    lead OTHER

Principal Investigators

  • Noha A. El bassiouny, Lecturer · Damanhour University

  • Mohamed Khalef, Ph.D · Maady Military Hospital

  • Mahmoud Abdallah, Ph.D. · International Medical Center (IMC) Hospital, Cairo, Egypt.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-11
Primary Completion
2023-12-30
Completion
2023-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05813132 on ClinicalTrials.gov